What is Roth Capital’s Forecast for Beyond Air Q3 Earnings?

Beyond Air, Inc. (NASDAQ:XAIR) – Equities research analysts at Roth Capital boosted their Q3 2025 earnings estimates for shares of Beyond Air in a report issued on Tuesday, November 12th. Roth Capital analyst J. Wittes now anticipates that the company will earn ($0.23) per share for the quarter, up from their previous estimate of ($0.27). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Beyond Air’s current full-year earnings is ($0.92) per share. Roth Capital also issued estimates for Beyond Air’s Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.01) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.53) EPS.

Other equities analysts have also issued research reports about the stock. Roth Mkm restated a “buy” rating and set a $2.00 target price on shares of Beyond Air in a research report on Friday, August 16th. Piper Sandler dropped their price objective on shares of Beyond Air from $3.50 to $1.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $3.67.

Beyond Air Trading Down 5.4 %

Shares of XAIR opened at $0.50 on Friday. The firm has a market cap of $23.67 million, a P/E ratio of -0.38 and a beta of -0.18. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.76 and a quick ratio of 2.42. Beyond Air has a 1 year low of $0.30 and a 1 year high of $2.36. The company has a 50 day simple moving average of $0.41 and a two-hundred day simple moving average of $0.68.

Beyond Air (NASDAQ:XAIR) last released its earnings results on Monday, November 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.02. Beyond Air had a negative return on equity of 227.29% and a negative net margin of 2,369.17%. The firm had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $1.19 million. During the same quarter last year, the business posted ($0.51) earnings per share.

Insider Activity at Beyond Air

In other Beyond Air news, CEO Steven A. Lisi purchased 1,476,626 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was purchased at an average price of $0.50 per share, with a total value of $738,313.00. Following the acquisition, the chief executive officer now owns 3,249,411 shares in the company, valued at approximately $1,624,705.50. The trade was a 83.29 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 20.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Beyond Air

Several large investors have recently added to or reduced their stakes in XAIR. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Beyond Air in the 2nd quarter worth approximately $47,000. Soros Fund Management LLC bought a new stake in Beyond Air in the third quarter worth $573,000. Vanguard Group Inc. boosted its stake in Beyond Air by 5.0% during the first quarter. Vanguard Group Inc. now owns 1,399,298 shares of the company’s stock worth $2,435,000 after buying an additional 66,224 shares during the period. Finally, Gendell Jeffrey L increased its position in Beyond Air by 30.4% during the first quarter. Gendell Jeffrey L now owns 1,461,071 shares of the company’s stock valued at $2,542,000 after acquiring an additional 340,774 shares during the last quarter. 31.50% of the stock is owned by institutional investors.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.